MRA advances for PAD and aorta (non-contrast techniques, vessel wall imaging)

in Vascular Diagnostics and Imaging

Applied

Type

Modification

Confidence

88%

Created

Apr 14, 2026

Evidence

1 source

Rationale

The 2024 ACC/AHA/SVS Lower Extremity PAD guideline (PMID 38743805) supersedes the 2016 AHA guideline cited in the final sentence for the claim about modality selection guidance. Rather than adding a duplicate citation alongside the stale one, the stale Patel MR, et al citation is replaced with the existing chapter key acc 2025, which already refers to this 2024 guideline. No new citation key is needed. No other substantive content changes are warranted, as the article does not introduce new technique-level detail beyond what is already covered in the section.

Content Changes

**magnetic resonance angiography (MRA) Advances for peripheral arterial disease (PAD) and Aorta: Non-Contrast Techniques and Vessel Wall Imaging**

Magnetic resonance angiography has evolved to include multiple technique options that expand its clinical applicability:

**Non-contrast MRA techniques:** When gadolinium-based contrast is contraindicated (e.g., severe renal insufficiency, prior allergic reaction), non-contrast MRA sequences provide viable alternatives for vascular imaging. These include time-of-flight (TOF) and various flow-based techniques that do not require exogenous contrast agents.

**Contrast-enhanced MRA:** Where safe, CE-MRA remains the preferred MR technique, offering superior image quality and faster acquisition times compared to non-contrast methods.

**Vessel wall imaging:** Specialized MR sequences enable direct visualization of the arterial wall, proving particularly valuable in diagnosing and monitoring large vessel vasculitis and characterizing arterial dissection. These techniques provide information beyond luminal assessment alone.

MRA serves as an alternative first-line imaging modality in patients for whom computed tomography angiography (CTA) is inappropriate, with modality selection guided by disease characteristics and patient-specific factors according to major PAD and disease-specific guidance. [@prince2016] [@aha2016][@acc2025] [@esvs2019-aaa] [@esvs2018-esvs]